IPET 2020 – all you need to know about Theranostics
Event: IPET 2020, Beyond the visible - International Conference on [...]
Radiopharmaceuticals Emerging as New Cancer Therapy
National cancer Institute. October 26, 2020 The last years have [...]
EANM ’20 – Let’s talk Radiotheranostics!
Event: EANM 2020 Annual Meeting - Virtual Edition Date: 22-30 [...]
Cu-64-Diasparagine (CuASP)
64Cu-Diasparagine (64CuASP) is a 64Cu-labeled peptide developed for the imaging [...]
Cu-67-SARTATE
67Cu-SARTATE (67Cu-SAR-[Tyr3]-Octreotate) is a therapeutic radiolabeled somatostatin analogue of [...]
Lu-177-PSMA-R2
177Lu-PSMA-R2 was developed as patent protected equivalent of 177Lu-PSMA-617. This [...]
Lu-177-EB-PSMA-617
177Lu-EB-PSMA-617 is a PSMA-617 analogue developed in China as an [...]
Lu-177-DOTA-EB-TATE
177Lu-DOTA-EB-TATE is a theranostic agent based on octreotate that uses [...]
Lu-177-Debio-1124
177Lu-Debio 1124 is a second-generation radiolabeled peptide analogue of minigastrin [...]
Lu-177-CTT-1403
177Lu-CTT1403 is the therapeutic analogue of 18F-CTT1057, a phosphoramide based [...]